Antenatal Myo-inositol Supplementation in Pre-existing Diabetes
This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.
Pregnant women aged 21 years to 45 years old at the time of recruitment [+6]
Known or suspected fetal aneuploidy or genetic/structural anomaly [+1]